SCHEMBL6984525

SCHEMBL6984525

CCCC(CC(=O)N1CCN(c2ccc(OC)cc2)CC1)NC(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GFER P55789 4/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 1/20 0.45
KDM4E B2RXH2 2/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 1/20 0.43
AKR1C3 P42330 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985573 0.89 CASP1 (0.46) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL6981146 0.89 ALDH1A1 (0.45) GFERKMT2AMEN1HSD17B10L3MBTL1
SCHEMBL6981304 0.89 CNR1 (0.44) GFERMAPTKMT2AMEN1CYP2C9
SCHEMBL6985160 0.83 MEN1 (0.48) MAPK1KMT2AMEN1NPSR1ALDH1A1
SCHEMBL6981707 0.80 SMN1; SMN2 (0.43) MAPTKMT2AMEN1HTTNPSR1
SCHEMBL6984518 0.77 L3MBTL1 (0.49) MAPK1MAPTKMT2AMEN1HSD17B10
SCHEMBL6983402 0.75 NPC1 (0.54) KMT2AMEN1NPSR1ALDH1A1KDM4E
SCHEMBL6979227 0.74 GAA (0.39) MAPK1KMT2ANPSR1L3MBTL1ALDH1A1
SCHEMBL6978571 0.72 KMT2A (0.44) MAPTKMT2AMEN1HTTNPSR1
SCHEMBL2766451 0.71 POLB (0.67) GFERMAPK1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed